Browsing: Wellness Tips

NEW YORK –New York City sanitation workers are reporting an increase in needle-stick injuries; a trend the city’s Sanitation Department says may be linked to a growing number of residents using needles for GLP-1 weight-loss medications

It has been 12 years since the first GLP-1 receptor agonist, liraglutide (Saxenda), was approved as a weight loss medication. This breakthrough was followed in 2021 by the approval of semaglutide (Wegovy) and in 2023 by the approval of tirzepatide (Zepbound), which have transformed obesity treatment

— Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan —

Follow Us 0% `; } fg = container.querySelector(“.sp-fg”); text = container.querySelector(“.sp-text”); render(); } const clamp = (n, min, max) => Math.max(min, Math.min(max, n)); function getProgress() { const rect = article.getBoundingClientRect(); const vh = window.innerHeight; const total = rect.height – vh; if (total = 1 && p < 100) { if (removeTimer) { clearTimeout(removeTimer); removeTimer =…

Ayeesha Walsh Mon, August 24, 2026 at 11:01 AM UTC Tammy Slaton used to look very different -Credit:tlc/Instagram

Hanmi Pharmaceutical will license a next-generation obesity drug candidate designed to reduce body weight while preserving muscle to Genentech, a subsidiary of Swiss drugmaker Roche, in a deal worth up to 3.2 trillion won ($2.3 billion)

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in

Federal regulators are turning up the heat on sellers of copycat weight-loss drugs. Earlier this summer, theFood and Drug Administration sent warning letters to dozens of companies marketing compounded GLP-1s over misleading advertising

To test whether stochastic vibrotactile stimulation (SVS) improved early weight trajectories in hospitalized term newborns with prenatal opioid exposure

A woman in her forties walks into a pharmacy this week and, for the first time, finds a weight-loss prescription she can plausibly afford without dipping into savings. Foundayo, Eli Lilly’s oral orforglipron tablet, costs somewhere between a hundred and a hundred and eighty pounds a month depending on dose and retailer, well under the…